Meet MiniMed Ambassador, Caroline Smyth. She’s a young college student who appreciates the new design of the MiniMed 630G system. Hear what she has to say about her latest experience.
My experience on an insulin pump started about 2 years after my diagnosis with diabetes. Imagine a 12 year-old and a device that sort of (not exactly) resembled a medical resident’s pager. I was constantly asked questions about why I had a pager and what it was for. Considering I had not been to medical school and had only been on planet earth for about twelve years, these were difficult questions to answer and discuss. Especially since I didn’t want any of my friends or classmates to know about my diabetes in the first place.
There were a few years where I decided that instead of receiving the best possible care by continuing to use my pump, I resorted back to using insulin pens. It wasn’t until entering high school that I decided enough was enough. I needed to do what was best for my management and diabetes care and not make choices regarding the annoying and pestering questions I was receiving about my insulin pump.
This past June I had the pleasure of attending the 76th Annual Scientific Sessions which is a conference where upcoming future diabetes medical devices are given a sort of first glance. Upon attending, I fell in love. No, it was not the array of doctors from around the world, or even the vast amount of people who were excited about diabetes care and treatment. Instead I got to see previews of the new MiniMed pump platform and knew I needed to get myself on the waitlist.
Fast forward to August. Medtronic released news of the MiniMed 630G system! I was over the moon! Receiving a new design for my medical device was the coolest thing to ever happen to me.
The day the brown Medtronic box arrived on my doorstep was extremely exciting. This was the first pump that had a completely different face – um did I add that it also has a color screen?! This was huge for a type 1 like myself. After tearing open the brown box I was introduced to some fancy and sleek packaging. The white box resembled that of a new apple product, with its simplistic but sleek packaging. I couldn’t wait to get started.
I now feel like a much more high-tech, stylish person with diabetes when I navigate the instructions on the bright color screen of my new black pump. Long gone are the days of my insulin pump being mistaken for a pager and instead I am receiving questions from others living with diabetes wondering how they too can get this new system. I am ecstatic and overwhelmed by the idea that this beautiful and sophisticated piece of technology is my new normal. That I finally have a pump that looks like its own unique and special device. My device now matches anything I want to wear, and makes it easy for me to accomplish my daily tasks.
Of course a first notion would be that switching from one medical device to another- especially when the devices are so vastly different in a plethora of ways – would usher unease, but I was inexplicably comfortable. I also have never used a CGM before receiving my MiniMed 630G system and was incredibly impressed with how the two devices work together and function as one operating unit.
My level of enthusiasm regarding a new insulin pump may come off as odd to someone who doesn’t have a device physically connected to their body for 24 hours a day. But, I think it’s important for someone to wear a device that helps motivates you. Every time I look at my insulin pump, it makes me want to work harder. Work harder at getting my A1c to a better level or work harder at making my life exactly what I want it to be. My new pump has given me a level of confidence that I’ve never had before in a medical device. I adore what helps me sustain my life even more so than I did before.
The MiniMed 630G system has changed my life in more ways than I could even express and I’m forever grateful to Medtronic for not just wanting to make life-changing products, but also products that give personality back to a person with a device that feels unique and original. A device as unique as the person wearing it.
Caroline will be among the first of many who are first in line to receive the MiniMed 670G system by participating in the Priority Access program. If you’re interested in learning more about how you can get the MiniMed 630G system now and then transition to the MiniMed 670G system please visit: http://www.medtronicdiabetes.com/products/priority-access
Important Safety Information
The MiniMed 530G and 630G systems with SmartGuard technology are intended for the delivery of insulin and continuous glucose (CGM) monitoring for the management of diabetes mellitus in persons 16 years of age or older who require insulin. Insulin infusion pumps and associated components of insulin infusion systems are limited to sale by or on the order of a physician and should only be used under the direction of a healthcare professional familiar with the risks of insulin pump therapy. The systems are not intended to be used directly for preventing or treating hypoglycemia but to suspend insulin delivery when the user is unable to respond to the Threshold suspend (530G) or Suspend on low (630G) alarm and take measures to prevent or treat hypoglycemia themselves. The information provided by CGM systems is intended to supplement, not replace, blood glucose information obtained using a blood glucose meter. A confirmatory fingerstick via a CONTOUR®NEXT LINK portfolio meter*, is required prior to making adjustments to diabetes therapy. Always check the pump display when using a CONTOUR®NEXT LINK portfolio meter*, to ensure the glucose result shown agrees with the glucose results shown on the meter. Additional, warnings, precautions and contraindications apply. See www.medtronicdiabetes.com/support/download-library/user-guides and www.medtronicdiabetes.com/importantsafetyinformation for details.
MiniMed® 670G System
The Medtronic MiniMed 670G system requires a prescription and is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of Type 1 diabetes mellitus in persons, fourteen years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed 670G System includes SmartGuard technology, which can be programmed to automatically adjust delivery of basal insulin based on Continuous Glucose Monitor sensor glucose values, and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values.
The Guardian Sensor (3) is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a finger stick may be required. All therapy adjustments should be based on measurements obtained using a home glucose monitor and not on values provided by the Guardian Sensor (3).
WARNING: Medtronic performed an evaluation of the MiniMed 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely.
Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Do not use the serter on products other than the Enlite sensor or Guardian Sensor (3). Medtronic cannot guarantee the safety or efficacy of this product if used with other products. The reservoir is contraindicated for the infusion of blood or blood products. Infusion sets are indicated for subcutaneous use only and not for intravenous (IV) infusion or the infusion of blood or blood products. Insulin pump therapy is not recommended for those who are unwilling to perform at least four blood glucose tests per day. As insulin pumps use rapid acting insulin only, BG testing is required to help identify rapid glycemic deterioration due to insulin infusion occlusion, infusion site problems, insulin stability issues, user error, or a combination of these. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional.
The safety of the 670G system has not been studied in people with impaired kidney function. Please let your healthcare professional know if you have kidney disease so you and your healthcare professional can determine if the potential benefits of using the system outweigh the risks. The safety of the 670G system has not been studied in pregnant women, people with type 2 diabetes, or in people using other anti-hyperglycemic therapies apart from insulin. Please let your healthcare professional know if any of these conditions apply to you so you and your healthcare professional can determine if the potential benefits of using the system outweigh the risks.
For complete safety information, please consult the appropriate User Guide.
*The CONTOUR®NEXT LINK 2.4 Meter is used with the MiniMed 630G and 670G systems. The CONTOUR®NEXT LINK Meter is used with the MiniMed 530G system.
, MiniMed 630g
, minimed 670g
, Priority Access
, type 1 diabetes